Finn
PBH Consumer Health · OTC brands · Defensive demand · Buybacks · Thesis updated November 8, 2026

New brands mask a stalled eye care recovery

01 Running thesis

Buying growth while waiting on supply

The core PBH thesis is based on owning small but useful health brands that generate steady cash. People buy products like eye drops, yeast infection treatments, hydration powders, earwax removers, and sleep aids because they need them, not because they are trendy.

The main problem remains Clear Eyes. A long supply issue kept PBH from meeting demand, and the recovery timeline has been pushed out again after October production shortfalls at the Pillar5 facility. Management now expects under 20 million dollars in Clear Eyes sales for fiscal 2027, delaying any meaningful recovery to fiscal 2028.

To fill the growth void, PBH is leaning on its acquisitions. Breathe Right brings about 200 million dollars in annual revenue and is now the largest brand in the portfolio. The company is also seeing an unexpected boost in its stomach care segment, as Dramamine sales rise to help GLP-1 users manage nausea.

The bear case asks if PBH can ever run its newly acquired Pillar5 facility well enough to rebuild Clear Eyes shipments, and whether it can integrate new acquisitions without losing focus. The bull case points to the immediate scale from Breathe Right masking the near term headwinds.

Nov 2026▼Q2 fiscal 2027 earnings showed October production shortfalls at Pillar5 derailing the Clear Eyes recovery, pushing it to fiscal 2028. However, Breathe Right is now the largest brand and Dramamine is seeing GLP-1 tailwinds.
Aug 2026→Q1 fiscal 2027 results showed Clear Eyes sales dropping below 3 percent of the total, pushing the recovery timeline out further. The completion of the Breathe Right and LaCorium acquisitions pivots the near term story to portfolio diversification.
May 2026→Fiscal 2026 Q4 and Full Year results highlighted continued strength in pricing, though overall growth remains constrained by the Clear Eyes supply chain integration following the December 2025 Pillar5 acquisition.
Feb 2026→Pillar5 closed in December 2025, which de-risks future Clear Eyes supply. Q3 revenue still fell 2.4 percent, so the thesis shifts from finding supply to executing the recovery.
Nov 2025▲Q2 showed Clear Eyes supply improving, with Pillar5 commercial product expected to ship later in the quarter. PBH also repurchased over 1.1 million shares while holding leverage at 2.4x.
Aug 2025▼Q1 exposed a worse Clear Eyes supply problem after a planned shutdown lasted longer than expected. PBH responded by agreeing to buy Pillar5 for about 100 million dollars in cash.
May 2025→Fiscal 2025 confirmed the Summer's Eve turnaround and International strength, but management also flagged about 15 million dollars of fiscal 2026 tariff risk. Capital allocation also moved more toward M&A and buybacks.
Feb 2025▲Q3 fiscal 2025 beat expectations with record quarterly sales and EPS. Summer's Eve returned to growth, International grew about 8 percent excluding foreign exchange, and Clear Eyes was still expected to recover slowly.
02 Business model

Small health brands, steady cash

PBH makes money by selling over-the-counter healthcare products to retailers. Over-the-counter means products people can buy without a prescription. The company spends on marketing, packaging, product updates, and retailer relationships to keep its brands on shelves and in online carts.

This model works well because the products are low cost and needs based. A consumer with dry eyes, heartburn, dehydration, or a cold usually wants a trusted fix. PBH does not need to invent a new medicine every year to stay relevant.

The weak spot is operations. If PBH cannot make enough product, retailers cannot sell it. Clear Eyes showed how a supply chain issue can turn a steady brand into a drag on revenue. Owning Pillar5 was supposed to reduce that risk, but zero safety stock and recent production misses show PBH is still struggling to run the manufacturing side.

Capital allocation is a key part of the story. The company generates strong free cash flow, which it uses for share repurchases and strategic acquisitions like Breathe Right and LaCorium.

03 Product portfolio

Where the brands fit

Option

Eye & Ear Care

Clear Eyes is the key recovery brand, with TheraTears and Debrox also in the group. Production shortfalls have pushed recovery expectations out to fiscal 2028.

Cash cow

Women's Health

Monistat and Summer's Eve are important brands in this group. This category provides steady performance.

Growth engine

Wellness, Sleep and Other

Formed by the Breathe Right acquisition, which is now the largest brand in the portfolio, generating about 200 million dollars annually.

Steady

Gastrointestinal and Pediatric

Reliable segments offering unexpected growth tailwinds, as Dramamine benefits from nausea side effects experienced by GLP-1 users.

Steady

International

Led by Hydralyte in Australia and recently strengthened by the LaCorium Health acquisition.

04 Business segments

Mostly North America

North American OTC Healthcare84%flat
International OTC Healthcare16%modest

The mix reflects fiscal 2026 annual segment revenue before the new acquisitions. North American OTC Healthcare was 83.9 percent of revenue, with International OTC Healthcare at 16.1 percent. The new wellness and sleep category will alter this pro forma mix.

05 Risk factors

What could break the thesis

Integration of new brands

High impact · Medium odds

PBH just added significant revenue through Breathe Right and LaCorium. If management struggles to integrate these brands while also trying to fix Pillar5, overall growth could stall.

We watchPerformance of the new wellness and sleep category in upcoming quarters.

Pillar5 integration misses

High impact · High odds

PBH bought Pillar5 to control more of the Clear Eyes supply chain. Recent October production shortfalls and zero safety stock show the facility is still highly volatile.

We watchClear Eyes shipment growth and management comments on Pillar5 production capacity.

Clear Eyes share does not come back

High impact · Medium odds

Even as supply improves, shoppers may have tried rival eye drops during the shortage. Retailers may also have given shelf space to competitors permanently.

We watchClear Eyes market share, retail inventory, and signs of higher promotion spending.

E-commerce orders stay noisy

Medium impact · High odds

Management has called out volatile order patterns from a major e-commerce retailer. Those orders can move quarterly sales even when consumer demand is steadier.

We watchRetailer order timing versus consumption trends in management commentary.
06 Quick answers

In one breath

What does Prestige Consumer Healthcare do?

PBH owns and sells over-the-counter healthcare brands. Its products include eye drops, women's health products, sleep aids, hydration, and stomach care.

Why does Clear Eyes matter so much for PBH?

Clear Eyes has been a major source of pressure because PBH could not make and ship enough product. The brand will generate under 20 million dollars in fiscal 2027, making its fiscal 2028 recovery a key focus.

Is PBH mainly a growth stock or a cash flow stock?

Right now it looks more like a cash flow and portfolio integration story. Growth from new acquisitions is masking the ongoing supply issues in the core eye care business.

What is the next thing investors should watch?

Watch whether the new Breathe Right brand maintains its revenue targets. The second signal is whether Clear Eyes production at Pillar5 finally stabilizes ahead of fiscal 2028.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. PBH Fiscal 2027 Q2 Earnings Transcript
  2. PBH Fiscal 2027 Q1 Form 10-Q
08 Explore the industry

Comparable Drug Manufacturers - Specialty & Generic companies

Companies near Prestige Consumer Healthcare Inc. in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

Get started with Finn today